.gif)
A team has found that their drug Molnupiravir (MK-4482/EIDD-2801) acts as an antiviral against SARS-CoV-2 in pre-clinical studies.
A team has developed a new potential antiviral drug to combat infection from SARS-CoV-2, the virus causing the COVID-19 pandemic. Named Molnupiravir (MK-4482/EIDD-2801), the molecule was originally developed by Emory University, US, and was licensed by Ridgeback Biotherapeutics for development, in collaboration with Merck.
The study was conducted at the Institute for Biomedical Sciences at Georgia State University, US. The group, led by Dr Richard Plemper, originally discovered that the drug is potent against influenza viruses and completely suppresses virus transmission within 24 hours.
Source:https://www.drugtargetreview.com/news/77877/oral-drug-blocks-sars-cov-2-transmission-in-ferrets-researchers-find/
International Journal of Water Technology and Treatment Methods also provide the state of the art
Annals of Physical Medicine and Physiotherapy is an open access, peer reviewed, scholarly journal
Bulletin of Proteomics & Bioinformatics publishes the highest quality scientific articles
Current Trends In Medical And Clinical Case Reports is an open access monthly journal publishing Ca
International Journal of Methods and Protocols primary research papers presenting or using new or
Multidisciplinary Research and Reviews is an international, peer reviewed, open access, scien
Clinical Biostatistics And Biometrics OA is an international, peer reviewed, open access journal o
Bulletin Of Chemical Engineering publishes a broad-based journal found on two key tenets: To publi
.png)
.jpg)
